ATTR cardiac amyloidosis antibody drug pipeline

Clearing established amyloid deposits from the heart — not merely slowing their formation — is the defining unmet need in ATTR cardiac amyloidosis. This report maps the antibody depletion pipeline: patent assignees, clinical signals, and the emerging evidence that cardiac remodeling after fibril clearance is biologically achievable.